Prevalence of tumor necrosis factor alpha inducing protein (tipα) gene of Helicobacter pylori and its association with upper gastrointestinal diseases in India

Abstract

Background: Helicobacter pylori (H. pylori) is known to cause several gastro-duodenal diseases including chronic Gastritis, Peptic Ulcer disease and Gastric Cancer. Virulent genes of H. pylori like cagA, vacA are known to be responsible for the disease pathogenesis. But these virulence genes are not always found to be associated with disease outcome in all populations around the world. Relationship of H. pylori with Gastro Esophageal Re ux Diseases is controversial and uncertain. Tumor necrosis factor alpha inducing protein tipα is a new discovered virulent gene of H. pylori and is an inducer of certain cytokines and chemokines that are responsible for causing stomach cancer. Therefore, we conducted a study which aims to nd the prevalence of tipα gene in the Indian population and its association with H. pylori related upper gastrointestinal diseases.Results: The current study shows the prevalence rate of tipα gene in the Indian population to be 59.9%. Our study has found a signi cant association (p < 0.05) of tipα gene with Non Ulcer Dyspepsia (NUD) and also an association of cagA and vacAs1m1 with Gastritis and Duodenal Ulcer. Conclusion:Our study demonstrates for the rst time the presence of tipα as virulent factor of H. pylori strain in Indian population isolated from patients suffering from upper gastrointestinal diseases. Further, tipα is signi cantly associated with NUD but not with other upper gastrointestinal diseases in India.

Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight

“…Thus, this technique provides a new horizon for improving the clinical outcomes of diabetic patients suffering from DFU. Nevertheless, future studies are required to address some issues in this field including investigating the possibility of unrestricted cell differentiation and the development of tumors after receiving MSC therapy; (Han et al, 2022); introducing methods to obtain high levels of MSCs with the utmost purity; and (Mahant et al, 2021) optimizing methods to evaluate the long-term efficacy of MSCs. Dash, N. R., Dash, S. N., Routray, P., Mohapatra, S., and Mohapatra, P. C. (2009).…”